Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCP-AtorFen
- Development stage
- Unknown
- Lead developer
- Veloxis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LCP-AtorFen is a fixed-dose combination product of atorvastatin (the active ingredient of Lipitor) and fenofibrate (the active ingredient of Tricor) developed using LifeCycle Pharma's proprietary MeltDose technology. It is designed as a once-daily tablet for the treatment of mixed dyslipidemia, addressing three primary cardiovascular risk factors: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). The combination provides a convenient single pill once-daily dosing regimen without food effect.
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on LCP-AtorFen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCP-AtorFen.